- About this Journal
- Abstracting and Indexing
- Aims and Scope
- Article Processing Charges
- Articles in Press
- Author Guidelines
- Bibliographic Information
- Citations to this Journal
- Contact Information
- Editorial Board
- Editorial Workflow
- Free eTOC Alerts
- Publication Ethics
- Submit a Manuscript
- Subscription Information
- Table of Contents
Lung Cancer International
Volume 2012 (2012), Article ID 354657, 6 pages
Treatment of Non-Small-Cell Lung Cancer with Erlotinib following Gefitinib-Induced Hepatotoxicity: Review of 8 Clinical Cases
1Department of Thoracic Oncology, National Hospital Organization Toneyama National Hospital, 5-1-1 Toneyama, Toyonaka, Osaka 560-8552, Japan
2Pharmaceutical Department, National Hospital Organization Toneyama National Hospital, Toyonaka, Osaka, Japan
Received 15 May 2012; Revised 4 October 2012; Accepted 8 October 2012
Academic Editor: Ladislav Tomasek
Copyright © 2012 Yukihiro Yano et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- N. Thatcher, A. Chang, P. Parikh et al., “Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer),” The Lancet, vol. 366, no. 9496, pp. 1527–1537, 2005.
- T. J. Lynch, D. W. Bell, R. Sordella et al., “Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib,” The New England Journal of Medicine, vol. 350, no. 21, pp. 2129–2139, 2004.
- J. G. Paez, P. A. Jänne, J. C. Lee et al., “EGFR mutations in lung, cancer: correlation with clinical response to gefitinib therapy,” Science, vol. 304, no. 5676, pp. 1497–1500, 2004.
- W. Pao, V. Miller, M. Zakowski et al., “EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib,” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 36, pp. 13306–13311, 2004.
- M. Maemondo, A. Inoue, K. Kobayashi et al., “Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR,” The New England Journal of Medicine, vol. 362, no. 25, pp. 2380–2388, 2010.
- T. Mitsudomi, S. Morita, Y. Yatabe et al., “Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial,” The Lancet Oncology, vol. 11, no. 2, pp. 121–128, 2010.
- C. Ho, J. Davis, F. Anderson, G. Bebb, and N. Murray, “Side effects related to cancer treatment: case 1. Hepatitis following treatment with gefitinib,” Journal of Clinical Oncology, vol. 23, no. 33, pp. 8531–8533, 2005.
- P. Carlini, P. Papaldo, A. Fabi et al., “Liver toxicity after treatment with gefitinib and anastrozole: drug-drug interactions through cytochrome p450?” Journal of Clinical Oncology, vol. 24, no. 35, pp. e60–e61, 2006.
- N. Seki, K. Uematsu, R. Shibakuki, and K. Eguchi, “Promising new treatment schedule for gefitinib responders after severe hepatotoxicity with daily administration,” Journal of Clinical Oncology, vol. 24, no. 19, pp. 3213–3214, 2006.
- M. Takeda, I. Okamoto, M. Fukuoka, and K. Nakagawa, “Successful treatment with erlotinib after gefitinib-related severe hepatotoxicity,” Journal of Clinical Oncology, vol. 28, no. 17, pp. e273–e274, 2010.
- G. Y. Ku, A. Chopra, and G. D. L. Lopes Jr., “Successful treatment of two lung cancer patients with erlotinib following gefitinib-induced hepatotoxicity,” Lung Cancer, vol. 70, no. 2, pp. 223–225, 2010.
- T. Kijima, T. Shimizu, S. Nonen et al., “Safe and successful treatment with erlotinib after gefitinib-induced hepatotoxicity: difference in metabolism as a possible mechanism,” Journal of Clinical Oncology, vol. 29, no. 19, pp. e588–e590, 2011.
- R. Maruyama, Y. Nishiwaki, T. Tamura et al., “Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer,” Journal of Clinical Oncology, vol. 26, no. 26, pp. 4244–4252, 2008.
- T. S. Mok, Y. L. Wu, S. Thongprasert et al., “Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma,” The New England Journal of Medicine, vol. 361, no. 10, pp. 947–957, 2009.
- D. H. Lee, S. W. Kim, C. Suh, D. H. Yoon, E. J. Yi, and J. S. Lee, “Phase II study of erlotinib as a salvage treatment for non-small-cell lung cancer patients after failure of gefitinib treatment,” Annals of Oncology, vol. 19, no. 12, pp. 2039–2042, 2008.
- B. C. Cho, C. K. Im, M. S. Park et al., “Phase II study of erlotinib in advanced non-small-cell lung cancer after failure of gefitinib,” Journal of Clinical Oncology, vol. 25, no. 18, pp. 2528–2533, 2007.
- S. H. Sim, S. W. Han, D. Y. Oh et al., “Erlotinib after Gefitinib failure in female never-smoker Asian patients with pulmonary adenocarcinoma,” Lung Cancer, vol. 65, no. 2, pp. 204–207, 2009.
- T. Katayama, J. Shimizu, K. Suda et al., “Efficacy of erlotinib for brain and leptomeningeal metastases in patients with lung adenocarcinoma who showed initial good response to gefitinib,” Journal of Thoracic Oncology, vol. 4, no. 11, pp. 1415–1419, 2009.
- H. G. Yi, H. J. Kim, Y. J. Kim et al., “Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective for leptomeningeal metastasis from non-small cell lung cancer patients with sensitive EGFR mutation or other predictive factors of good response for EGFR TKI,” Lung Cancer, vol. 65, no. 1, pp. 80–84, 2009.
- K. Kubota, Y. Nishiwaki, T. Tamura et al., “Efficacy and safety of erlotinib monotherapy for japanese patients with advanced non-small cell lung cancer: a phase II study,” Journal of Thoracic Oncology, vol. 3, no. 12, pp. 1439–1445, 2008.
- H. Yoshioka, K. Hotta, K. Kiura et al., “A phase II trial of erlotinib monotherapy in pretreated patients with advanced non-small cell lung cancer who do not possess active egfr mutations: okayama lung cancer study group trial 0705,” Journal of Thoracic Oncology, vol. 5, no. 1, pp. 99–104, 2010.
- M. Reck, N. Van Zandwijk, C. Gridelli et al., “Erlotinib in advanced non-small cell lung cancer: efficacy and safety findings of the global phase IV Tarceva Lung Cancer Survival Treatment study,” Journal of Thoracic Oncology, vol. 5, no. 10, pp. 1616–1622, 2010.
- J. Li, M. Zhao, P. He, M. Hidalgo, and S. D. Baker, “Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes,” Clinical Cancer Research, vol. 13, no. 12, pp. 3731–3737, 2007.